Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals
Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has announced that it has received a milestone payment in the amount of $500,000 from Chong Kun Dang Pharmaceuticals the Korean distribution partner of Can-Fite BioPharma. This milestone payment is the second one, which is for completing patient enrollment in Europe, Israel and US for Phase II trials in advanced hepatocellular carcinoma. The trial will aim to assess the safety and efficacy of Namodenoson (CF102). Can-Fite has exclusive license to distribute this drug, which is being developed by CKD Pharmaceuticals.
Leafbuyer Technologies and Denver Post’s Cannabist have renewed their partnership
Leafbuyer Technologies, Inc., a leading cannabis technology company has announced that it has renewed its partnership with the Cannabist. Cannabist is a marijuana news website, and this renewal will continue their partnership of expanding consumer base of Leafbuyer and increase their brand identity. LeafBuyer Technologies CEO expects that 2018 will be a watershed year in this industry and they will grow with the Cannabist. The two companies already have a strong base in Colorado, and expect their presence to grow in Washington, Oregon, California, Arizona, Nevada and Michigan through this partnership.
EPX-300 of Epygenix Therapeutics and JOTROL of Jupiter has received Orphan Drug Designation for the treatment of Dravet Syndrome and Friedreich’s Ataxia respectively.
Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for catastrophic and rare forms of genetic epilepsy, has announced that the USFDA has granted Orphan Drug Designation for their drug EPX-300 for the treatment of patients with Dravet Syndrome. Additionally, Jupiter Orphan Therapeutics has also announced that they have received notification from the USFDA that its Orphan Drug Designation request for Trans-Resveratrol Product JOTROL for Treatment of Friedreich’s Ataxia has been granted.
New treatment Approved for adults with relapsed or refractory acute lymphoblastic leukemia by the USFDA
The USFDA has approved Pfizer’s Besponsa (inotuzumab ozogamicin) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults through a Priority Review and Breakthrough Therapy Designations. Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells. The approval is based on the clinical trial results carried out to check for the safety and efficacy of this drug in 326 adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Besponsa has also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.